ArticleJournal of the American Chemical Society2025
Proteomic Tracking Extracellular Vesicle RNA Interactors in Recipient Immune Cells through Orthogonal Labelings.
Article in Journal of the American Chemical Society, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Advances in the role of extracellular vesicles in circulating microRNA biomarker discovery for lung cancer.Frontiers in cell and developmental biology · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
Abstract
RNA cargos in extracellular vesicles (EVs) mediate intercellular communication by engaging RNA-binding proteins (RBPs) in recipient cells. Here, we introduce extracellular RNA interactome capture through orthogonal labelings (ERICOL), a targeted cross-linking and quantitative chemical proteomic strategy based on metabolic labeling of RNAs and stable isotope labeling of proteins for systematic profiling of EV RBPs in recipient cells. Time-resolved analysis of tumor-derived EVs in Jurkat T cells revealed dynamic patterns of EV RNA uptake and RBP engagement. Further profiling in primary human CD8+ T cells treated with wild-type or IDH1 mutant intrahepatic cholangiocarcinoma (ICC)-derived EVs uncovered IDH1 mutation-driven alterations in the EV RBP landscape. ERICOL offers a powerful strategy for comprehensive profiling of EV RNA interactome dynamics and provides mechanistic insights into EV-mediated immune modulation.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.